Celebrating Dr. David Segal: A Leader in Science and a Champion for Angelman Syndrome Research
FAST congratulates longtime research partner Dr. David J. Segal on his appointment as Chair of Biochemistry and Molecular Medicine at UC Davis, a milestone for the AS research community.
AS Natural History Study Celebrates 20 Years!
Celebrating 20 years of the Angelman Syndrome Natural History Study—decades of data, driven by families and researchers, that continues to fuel discovery and progress.
Reading the brain’s signals to speed better treatments for Angelman syndrome
FAST-funded research identifies peak alpha frequency, an EEG biomarker that could reveal early brain responses to Angelman syndrome treatment before day-to-day changes appear.
FAST-Funded Project Introduces First Large Animal Model to Study Angelman Syndrome
FAST-funded researchers at Texas A&M created the first-ever pig model of Angelman syndrome using CRISPR, offering a new platform that more closely mirrors human brain biology.
Inside INSYNC-AS 2025: Progress, Partnership, and Possibilities for Angelman Syndrome
The 5th Annual INSYNC-AS Meeting brought together top researchers to tackle brain-targeted drug delivery, sharing breakthroughs in blood-brain barrier crossing for Angelman syndrome therapies.
Investing in the Future of Angelman Syndrome Research: FAST Partners with ASGCT to Support Early-Career Scientists
FAST partners with ASGCT to fund up to three $100,000 Career Development Awards, recruiting early-career scientists to advance neuron-targeted gene and cell therapies for Angelman syndrome.”
FAST Announces Funding For First Innovative Seed Grant
FAST has awarded its first Innovative Seed Grant to Drs. Rachel Cunningham and Jennifer Adair to develop a safer, more accessible hematopoietic stem cell therapy approach for Angelman syndrome that avoids risky chemotherapy-based conditioning.
More Than a Seat at the Table: FAST’s Role in Shaping the Future of Angelman Syndrome at ASGCT 2025
FAST attended this year’s ASGCT conference, where Angelman syndrome was featured in 10 scientific presentations and multiple talks—proof the community is helping drive the future of gene and cell therapy.
FAST Speaks at the 2025 MENA Congress for Rare Diseases
FAST representatives Amelia Beatty and Ellen Koekoeckx presented at the MENA Congress for Rare Diseases in Abu Dhabi, highlighting the Angelman syndrome therapeutic pipeline and connecting with regional families and researchers.
Expanding the Pre-Clinical Research Landscape for Angelman Syndrome
FAST currently manages over 20 active research grants for Angelman syndrome and is expanding its infrastructure by broadening its Scientific Advisory Board and streamlining its grants management system.